#USA #New York #Securities Fraud #Bain Capital #Cerevel Therapeutics

Cerevel Therapeutics Holdings, Inc. Faces Class Action Lawsuit

Overview

Rosen Law Firm has initiated a class action lawsuit against Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) on behalf of investors who dealt with the company’s securities during a specific period. This legal action highlights allegations of misleading financial statements that potentially influenced investor decisions and led to significant losses.

Background

The lawsuit encompasses all individuals and entities who:
1. Sold or disposed of Cerevel’s stock between October 11, 2023, and August 1, 2024.
2. Held shares as of January 8, 2024, and were entitled to vote on the merger with AbbVie Inc.
3. Sold shares of Cerevel stock close to Bain Capital's stock purchases in mid-October 2023.

The Rosen Law Firm is calling upon affected investors to join the lawsuit, with the lead plaintiff position open for those willing to step forward with applications due by June 3, 2025.

The Allegations

According to the lawsuit, Cerevel's actions during this period were marred by deceptive practices. Specifically, statements made by Cerevel regarding its public stock offering on October 16, 2023, are under scrutiny. The firm claims that this secondary stock offering allowed key stakeholders—namely Bain Capital and Pfizer—to increase their holdings at a lower price, just before the public announcement of AbbVie’s intent to acquire Cerevel at significantly higher share prices.

This sequence of events allegedly resulted in Bain Capital profiting immensely, potentially exceeding $120 million, by benefiting from discounted stock rates shortly before the merger announcement.

How to Get Involved

Investors interested in joining the class action can do so through Rosen Law Firm’s submission page. Those seeking further information may reach out directly to Phillip Kim, Esq., via email at [email protected] or by phone at 866-767-3653.

Rosen Law Firm emphasizes that individuals need not pay out-of-pocket fees as they operate on a contingency basis. This means that legal costs will only be incurred upon a successful outcome in court.

The Importance of Choosing the Right Counsel

The firm encourages investors to opt for experienced legal representation that specializes in securities class actions. With a track record that includes securing the largest securities class action settlement against a Chinese company, Rosen Law Firm has proven itself as a stalwart advocate for investors. Its presence at the forefront of securities litigation positions them as a reliable choice for those seeking justice.

Founding partner Laurence Rosen has received high acclaim and recognition in the legal domain, underscoring the firm’s strong reputation and success rates in past litigations.

Conclusion

For investors of Cerevel Therapeutics, this class action lawsuit represents an opportunity to hold the company accountable for its alleged securities fraud and recover possible losses incurred. Immediate action is necessary to ensure participation, with the deadline for lead plaintiffs approaching rapidly. Investors are strongly advised to pursue further information to protect their interests and navigate the forthcoming legal challenges effectively.